136 related articles for article (PubMed ID: 1848372)
21. Neurologic protection by amifostine.
DiPaola RS; Schuchter L
Semin Oncol; 1999 Apr; 26(2 Suppl 7):82-8. PubMed ID: 10348265
[TBL] [Abstract][Full Text] [Related]
22. High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer.
Schiller JH
Semin Oncol; 1996 Aug; 23(4 Suppl 8):78-82. PubMed ID: 8783672
[TBL] [Abstract][Full Text] [Related]
23. High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observations.
DeGregorio MW; Gandara DR; Holleran WM; Perez EA; King CC; Wold HG; Montine TJ; Borch RF
Cancer Chemother Pharmacol; 1989; 23(5):276-8. PubMed ID: 2539912
[TBL] [Abstract][Full Text] [Related]
24. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
Thongprasert S; Chewaskulyong B
J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
[TBL] [Abstract][Full Text] [Related]
25. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher CM; Mallmann PK
Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer.
Tolcher AW
Semin Oncol; 1996 Feb; 23(1 Suppl 1):37-43. PubMed ID: 8629035
[TBL] [Abstract][Full Text] [Related]
27. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
28. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer.
Adamson PC; Balis FM; Belasco JE; Lange B; Berg SL; Blaney SM; Craig C; Poplack DG
Cancer Res; 1995 Sep; 55(18):4069-72. PubMed ID: 7664282
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological interventions to reduce platinum-induced toxicity.
Tognella S
Cancer Treat Rev; 1990 Sep; 17(2-3):139-42. PubMed ID: 2176930
[No Abstract] [Full Text] [Related]
30. [Can cisplatin renal toxicity be prevented?].
Brillet G; Deray G; Bunker D; Ben Hmida M; Baumelou A; Jacobs C
Nephrologie; 1991; 12(3):143-6. PubMed ID: 1922654
[TBL] [Abstract][Full Text] [Related]
31. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
Sastry J; Kellie SJ
Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
[TBL] [Abstract][Full Text] [Related]
32. Improved therapeutic index of cis-diammine dichloro platinum by diethyldithiocarbamate in rodents.
Khandekar JD
Res Commun Chem Pathol Pharmacol; 1983 Apr; 40(1):55-66. PubMed ID: 6306745
[TBL] [Abstract][Full Text] [Related]
33. [Preclinical and clinical evaluation of toxicity and antitumor activity of cisplatin analogues].
Ariyoshi Y; Ota K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1379-85. PubMed ID: 2658826
[TBL] [Abstract][Full Text] [Related]
34. Org.2766 protects from cisplatin-induced neurotoxicity in rats.
de Koning P; Neijt JP; Jennekens FG; Gispen WH
Exp Neurol; 1987 Sep; 97(3):746-50. PubMed ID: 3040462
[TBL] [Abstract][Full Text] [Related]
35. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
Links M; Lewis C
Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
[TBL] [Abstract][Full Text] [Related]
36. Ototoxicity of chemotherapeutic agents.
Schweitzer VG
Otolaryngol Clin North Am; 1993 Oct; 26(5):759-89. PubMed ID: 8233488
[TBL] [Abstract][Full Text] [Related]
37. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
Laryngoscope; 2004 Sep; 114(9):1660-7. PubMed ID: 15475801
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II trials of WR-2721 and cis-platinum.
Glover D; Glick JH; Weiler C; Fox K; Turrisi A; Kligerman MM
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1509-12. PubMed ID: 3019969
[TBL] [Abstract][Full Text] [Related]
39. Rationale for the use of the ACTH4-9 analogue ORG 2766 in the treatment of diabetic neuropathy.
Bravenboer B; Erkelens DW; Gispen WH
Neth J Med; 1992 Dec; 41(5-6):255-8. PubMed ID: 1337372
[No Abstract] [Full Text] [Related]
40. Protective effects of a neurotrophic ACTH(4-9) analog on cisplatin ototoxicity in relation to the cisplatin dose: an electrocochleographic study in albino guinea pigs.
Stengs CH; Klis SF; Huizing EH; Smoorenburg GF
Hear Res; 1998 Oct; 124(1-2):108-17. PubMed ID: 9822908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
